Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, M. D’Incan, Julia Scarisbrick et al.|The Lancet|2017Cited by 580
Avapritinib versus Placebo in Indolent Systemic MastocytosisJason Gotlib, Robyn M. Scherber, Mariana Castells et al.|NEJM Evidence|2023Cited by 74